Simultaneous expression of highly homologous RLN1 and RLN2 genes in prostate impairs their accurate delineation. We used PacBio SMRT sequencing and RNA-Seq in LNCaP cells in order to dissect the expression of RLN1 and RLN2 variants. We identified a novel fusion transcript comprising the RLN1 and RLN2 genes and found evidence of its expression in the normal and prostate cancer tissues. The RLN1-RLN2 fusion putatively encodes RLN2 isoform with the deleted secretory signal peptide. The identification of the fusion transcript provided information to determine unique RLN1-RLN2 fusion and RLN1 regions. The RLN1-RLN2 fusion was co-expressed with RLN1 in LNCaP cells, but the two gene products were inversely regulated by androgens. We showed that RLN1 is underrepresented in common PCa cell lines in comparison to normal and PCa tissue. The current study brings a highly relevant update to the relaxin field, and will encourage further studies of RLN1 and RLN2 in PCa and broader.
Relaxin is a mammalian hormone that is involved in reproduction. As the name suggests, relaxin is the component of serum that causes the relaxation of the pubic ligament in pregnant female prior to delivery (Fevold et al., 1930; Hisaw, 1926) . The human relaxin gene was first isolated from a cDNA library from the corpus luteum, and later confirmed and characterized by mass spectrometry Stults et al., 1990) . In apes and humans, the relaxin gene underwent a duplication generating two relaxin genes with high sequence similarity, relaxin-1 (RLN1) and relaxin-2 (RLN2). (Arroyo et al., 2014; Crawford et al., 1984) . RLN1 mRNA is expressed in the prostate, but RLN1 peptide has never been isolated and its function has not been explored yet (Garibay-Tupas et al., 2000; Gunnersen et al., 1996) . The ovaries and prostate are the two major sources of RLN2 in humans. The expression of RLN2 in ovaries is intermittent and increases during the luteal phase of the menstrual cycle, with highest levels being produced by the corpus luteum during pregnancy (Ivell et al., 1989) . In men, RLN2 is produced continuously by the prostate, and accumulates in the seminal fluid to increase sperm motility (Carrell et al., 1995; Winslow et al., 1992) . Outside normal physiology, RLN2 is a promoter of cancer progression in several different types of cancers (Nair et al., 2012) . In prostate cancer (PCa), RLN2 was shown to promote tumor growth and vascularisation, and was regulated by androgens (Feng et al., 2010; Silvertown et al., 2006; Thompson et al., 2010 Thompson et al., , 2006 . Inhibition of RLN2 signalling by a peptide antagonist in PCa showed promising therapeutic efficacy in preclinical studies (Feng et al., 2010; Neschadim et al., 2014) .
High homology between RLN1 and RLN2 in the context of simultaneous expression in prostate tissue hinders the accurate characterization and functional study of individual relaxin genes in the prostate. In addition to the canonical sequences, a 101 bp longer alternatively spliced variant of RLN2 was discovered in the prostate tissue (Gunnersen et al., 1996) . There are several more transcript variants predicted by automated computational analysis that are supported by mRNA and EST data as annotated in the Aceview database (Thierry-Mieg and Thierry-Mieg, 2006) . Standard mRNA determination methods like qPCR, microarray, and RNA-Seq all largely depend on gene annotation databases which are incomplete, and change frequently with the identification of novel transcripts. Recent development of PacBio single molecule real time (SMRT) sequencing techniques aids the identification of transcript variants due to the longer read lengths produced by this platform (Eid et al., 2009) . Although PacBio data are inherently error-prone, a level of consensus accuracy can be achieved by multiple sequencing passes around the SMRTBell libraries. Circular consensus sequences (CCS) are derived from the long, raw reads providing sufficient read-of-insert depth of coverage to improve CCS read accuracy to >98% (Travers et al., 2010) . Paired-end RNA-Seq can also be used to characterize the expression of alternatively spliced genes using a Sashimi Plot -this implements a mixture of isoforms (MISO) algorithm and displays alternative exon usage by splice junction reads as arcs connecting a pair of exons (Katz et al., 2015) .
The aim of the present study was to use PacBio derived long cDNA SMRT sequencing in LNCaP cells in order to dissect the expression of RLN1, RLN2, and their transcript variants, and to identify unique RLN1 and RLN2 regions for the purpose of more accurate characterization. We report on a novel abundantly expressed fusion transcript between RLN1 and RLN2. The RLN1-RLN2 fusion putatively encodes an alternative RLN2 isoform with an altered signal sequence domain that potentially changes the mode of secretion. We inspected publically available RNA-Seq datasets for evidence of RLN1-RLN2 fusion expression in normal and PCa tissues. The fusion has substantial sequence overlap with RLN1 and RLN2, however we designed unique RLN1-RLN2 fusion and RLN1 qPCR primers, and determined their expression in common PCa cell lines as well as defined their androgen regulation.
Materials and methods

Cell lines
Immortalized prostate epithelial cells RWPE-1 (ATCC CRL-11609) were grown in keratinocyte serum-free media supplemented with recombinant human epidermal growth factor (5 ng/ ml final concentration) and bovine pituitary extract (50 ng/ml). Immortalized prostate epithelial cells BPH-1, HPR-1, and PCa cell lines PC-3 (ATCC CRL-1435), 22RW1 (ATCC CRL-2505), DU145 (ATCC HTB-81), LNCaP (ATCC CRL-1740), C4-2B (from Dr Leland Chung, Cedars-Sinai Medical Center, USA), DuCaP (from Dr Matthias Nees, Faculty of Medicine, Turku University, Finland) were cultured in RPMI1640 supplemented with 5% FBS. LAPC4 cells were grown in IMDB medium supplemented with 5% FBS. HEK293T were cultured in high-glucose DMEM, supplemented with 2 mM Lglutamine and 1 mM sodium pyruvate and 10% heat inactivated FBS. All media and supplements were sourced from Gibco (Life Technologies, Mulgrave, VIC, AU). All cells were grown in a cell culture incubator at standard conditions (37 C, 5% CO 2 ).
PacBio sequencing
Clontech SMARTer cDNA Synthesis. Long cDNA was prepared from 1 mg of DNase-treated LNCaP total RNA using the Clontech SMARter PCR Synthesis Kit (Clontech Laboratories, Mountain View, CA, USA). Second-strand cDNA was prepared in sixteen PCR reactions with 2 ml undiluted first-strand cDNA, 0.24 mM Clontech 5 0 PCR Primer IIA and KAPA HiFi HotStart ReadyMix (Kapa Biosystems, Inc., Wilmington, MA, USA) for 14 cycles in the standard SMARTer PCR cycling conditions. The second-strand PCR production was purified and concentrated through a single QIAquick PCR Purification Kit (QIAGEN Sciences, Germantown, MD, USA) and the concentration was determined using the Qubit dsDNA HS Assay Kit (Life Technologies, Grand Island, NY, USA). cDNA-Capture and Amplification. The cDNA was hybridized with a custom NF1 probe set (Gutmann et al., 2013) . Here, 780 ng of the cDNA library was mixed with 5 mg Cot-1 DNA (Invitrogen, Carlsbad, CA, USA) and 100 ng of NF1 probe. Hybridization was carried out in the presence of NimbleGen hybridization buffers (Roche NimbleGen, Madison, WI, USA) and processed per NimbleGen's SeqCap EZ Library SR user guide instructions. The solutions were denatured and allowed to hybridize at 47 C for 72 h. Post hybridization and PCR steps are described in Cabanski et al. (2013) . In brief, we performed 14 PCR cycles for the enriched cDNA library. Pacific Biosciences Sample Prep and Sequencing. Captured cDNA was converted into a 2 kb Pacific Biosciences (Pacific Biosciences of California, Inc., Menlo Park, CA, USA) library, according to the standard protocol using 500 ng of captured genomic DNA or cDNA and the DNA Template Prep Kit 2.0 (250 bp e 3 Kb). The resulting libraries were prepared for sequencing with the P4 polymerase and C2 chemistry using the MagBead protocol and DNA/Polymerase Binding Kit P4. The libraries complexes were prepared with 30 pM library and a 10:1 ratio of P4 DNA polymerase to library. Each library complex was sequenced on two SMRT cells with 180 min movie lengths using the MagBead Standard Seq v2 protocol. Circular consensus sequences were called using the ReadsOnInsert_CCS protocol through the SMRT Portal interface. The minimum full pass and minimum predicted accuracy filters were set at 2 and 90%, respectively. Detection of RLN1-RLN2 fusion. The RLN1-RLN2 fusion was identified from full-length CCS reads spanning the length of the entire transcript. For a transcript to be reported, we required at least two independent CCS reads to contain identical nucleotide sequences over the entire length of the transcript.
Analysis of RNA-Seq
RNA-Seq from LNCaP cells. LNCaP cells were seeded in a 10 cm culture dish and treated with 10 nM dihydrotestosterone (DHT) as described in the section 'Short-term androgen deprivation assay' below. Total RNA was isolated using the Norgen RNA Plus extraction kit (Norgen, Acacia Ridge, QLD, AU). RNA-Seq was carried out on total RNA using an Illumina TruSeq Stranded mRNA Sample Prep Kit with Set A indexes (Illumina, Scoresby, VIC, AU) and sequenced on Illumina HiSeq2500 v4.0 platform (Kinghorn Centre for Clinical Genomics (KCCG), Sydney, NSW, AU). Sequencing reads were generated by quality trimming using Trimgalore v.03.7 (Babraham Institute, http://www.bioinformatics.babraham.ac.uk/projects/ trim_galore/) and aligned to the GRCh38/hg38 genome using STAR v.2.4.0j (Dobin et al., 2013) . RNA-Seq from normal and PCa tissue. Transcript splice-site usage was assessed on RNA-Seq data sets comprising 14 PCa tumors and adjacent benign tissue (Ren et al., 2012) . RNA-Seq reads were mapped using Tophat2 (GRCh37/Hg19 assembly), and splice sites were visualized using indexed BAM files and the Integrative Genomics Viewer (Kim et al., 2013; Robinson et al., 2011) . IlluminaHiSeq_RNASeqV2 from 193 samples generated by the TCGA Research Network were accessed at http://cancergenome.nih.gov/(September 4, 2013) and were analysed as previously described . Correction of the RLN1-RLN2 fusion sequence informed by Illumina RNA-Seq from LNCaP cells. We generated the bowtie (Langmead et al., 2009 ) index files for the corrected RLN1-RLN2-2 fusion transcript sequence (genome assembly GRCh38/Hg38 matched). The reads from Illumina RNA-Seq from LNCaP cells were then aligned to the RLN1-RLN2-2 fusion transcript and the bam file was generated and visualized in RNASeqBrower .
Inducible stable shRNA cell line models
Lentivirus particles were generated in HEK 293T host cells transfected with X-tremeGENE HP DNA Transfection Reagent (Roche, Sydney, NSW, AU) and inducible lentiviral pTRIPZ shRNA plasmids targeting either the androgen receptor (AR) (shAR), RLN2 (shRLN2), or a negative control (shNT) (Thermo-Fisher Scientific, Richlands, QLD, AU). The pCMV-8.2R lentiviral packaging plasmids and pCMV-VSVG were kindly provided by Dr Brett Hollier (Queensland University of Technology, Brisbane, QLD, AU). Virus particles were collected 48 h and 72 h after transfection, and filtered through 45 mm filters. Target cells (LNCaP) were infected with the virus supernatant and 8 mg/ml protamine sulphate (SigmaeAldrich, Castle Hill, NSW, AU). Transfected cells were then selected with 2 mg/ml Puromycin Dihydrochloride (Life Technologies, Mulgrave, VIC, Australia). We observed some cells expressing red fluorescent protein (RFP) indicating inducible promoter leakage; therefore we used an Astrios EQ cell sorter (Beckman Coulter, Lane Cove, QLD, Australia) to remove cells with leaky inducible promoter.
Inhibition of androgen signalling
Short-term androgen deprivation assay. LNCaP cells were seeded into T25 flasks, and incubated in RPMI1640 þ 5% FBS for 3 days. The medium was then changed to RPMI 1640 supplemented with 5% charcoal stripped serum (CSS) and incubated for 2 days, then changed to RPMI 1640 supplemented with 10 nM DHT or 1 nM R1881, and incubated for 48 h with DHT top-up at 24 h. The reference group was kept in CSS. Long-term androgen deprivation assay. LNCaP cells were seeded into T25 flasks and incubated in RPMI 1640 þ 5% FBS for 3 days. The medium was then changed to RPMI 1640 supplemented with 5% CSS, and incubated for 10 days with medium changes every 3 days. Inducible AR knock-down.
LNCaP cells were seeded onto T25 flasks and incubated in RPMI 1640 þ 5% FBS for 3 days. The medium was then changed to RPMI 1640 supplemented with 5% CSS, and incubated with or without 1 mg/ml of doxycyline (dox) for 48 h. The medium was then supplemented with 10 nM DHT, and incubated for 48 h. The reference group was kept in CSS.
Quantitative real-time PCR
Total RNA was extracted using the RNAeasy Kit (Qiagen, Chadstone Centre, VIC, AU) before reverse transcription with SuperScript III Reverse Transcriptase (Life Technologies, Mulgrave, VIC, AU) according to the manufacturer's protocol. Subsequent quantitative PCR (qPCR) was carried out on the ViiA7 or 7900HT Real-Time PCR System (Life Technologies, Mulgrave, VIC, AU) with SYBR Green, or using Universal TaqMan detection (Life Technologies, Mulgrave, VIC, AU). Gene expression was determined using the 2 ÀDDCt method, and normalized to the housekeeping gene RPL32. Data is expressed relative to the reference group. Experiments were repeated a minimum of 3 times. Primer sequences are detailed in the Supplementary Table 1.
Statistical analysis
Results are representative of at least three independent experiments with triplicate samples generating similar findings. Differences between experimental groups were statistically evaluated by multiple t-tests, followed by the HolmeSidak test for multiple comparisons. p 0.05 was considered statistically significant. Statistical analysis was performed using Prism 6 (GraphPad Software Inc.).
Results
Identification of novel RLN1-RLN2 fusions in PCa
To comprehensively identify RLN1 and RLN2 transcript variants, we used long cDNA-Cap and SMRT sequencing in LNCaP cells, and queried for circular consensus sequences (CCSs) that mapped to the RLN1-RLN2 locus. We found CCSs identical to the annotated RLN1 gene, but interestingly, no CCS corresponded to the annotated RLN2 gene (GENCODE Version 19). Instead, the search retrieved sequences of two longer RLN2 transcript variants which were fused to the RLN1 gene, generating two fusion transcripts RLN1-RLN2-1 and RLN1-RLN2-2 (Fig. 1,  Supplementary Fig. S1 ). The inherent error-proneness of the SMRT sequencing technology hindered the determination of the Fig. 1 . Identification of the RLN1-RLN2 fusion in LNCaP cells using SMRT sequencing. The figure was extracted from the UCSC Genome Browser where the circular consensus sequences (CCS) of RLN1 and RLN2 identified by SMRT sequencing were aligned to the RLN1/RLN2 genomic locus using BLAT tool. GENCODE Version 19 annotated RLN1 and RLN2 transcript variants are shown in black. Combined CCS sequences of RLN1 are shown in orange and RLN1-RLN2 fusion CCS transcripts in blue. The arrowed-line represents introns and show directionality of the transcripts. The golden rectangles show an overlay between the annotated RLN1 and RLN2 and the transcripts identified by SMRT sequencing. (For interpretation of the references to color in this figure caption, the reader is referred to the web version of this article.) precise nucleotide sequence of the fusion transcripts. Therefore, we aligned the sequences of the novel fusion transcripts RLN1-RLN2-1 and RLN1-RLN2-2 to the human genome assembly GRCh38/hg38 using the Blat tool in the UCSC genome browser (Kent, 2002; Kent et al., 2002) . The sequences of the fusion transcripts were then corrected to match the genomic sequence. In order to increase the degree of certainty of the fusion transcript sequence, we mapped individual sequencing reads generated by a standard Illumina paired-end RNA-Seq from LNCaP cells to the corrected RLN1-RLN2-2 fusion sequence. We utilized a recently in-house developed RNASeqBrowser tool and observed that the raw sequencing reads perfectly aligned to the corrected sequence of the RLN1-RLN2-2 fusion, confirming its legitimacy (Supplementary Fig. S2 ). The mapping of raw sequencing reads highlighted only 3 differences in the nucleotide sequence of the RLN1-RLN2-2 fusion that could be ascribed to the difference between the human genome assembly GRCh38/hg38 and LNCaP genome (Supplementary Fig. S2 ). To additionally confirm the expression of the RLN1-RLN2 fusion transcripts, we analysed Illumina paired-end RNA-Seq from LNCaP cells using Sashimi Plot representation of RNA-Seq data in the Integrative Genomic Viewer. Sashimi Plots display alternative exon usage by drawing splice junction reads as arcs connecting a pair of exons (Katz et al., 2015) . Both novel fusion transcripts RLN1-RLN2-1 and RLN1-RLN2-2 were clearly observed in the Sashimi Plot of RNA-Seq from LNCaP cells ( Fig. 2A) . We then inspected Ren et al. RNA-Seq data comprising PCa tumors and adjacent benign tissue, and found similar splice junction reads between exons of novel fusion transcripts to those in LNCaP cells, suggesting broader representation of the RLN1-RLN2 fusion (Fig. 2B, C) (Ren et al., 2012) . In support of the newly identified RLN1-RLN2 fusion transcript the sequence of a similar longer RLN2 variant was recently predicted by an automated computational analysis that was supported by mRNA and EST evidence (accession number: XM_011518003.1, March 2015) ( Supplementary Fig. S3 ).
Novel RLN1-RLN2 fusion has an alternative putative ORF
The novel RLN1-RLN2 fusion transcripts contained incomplete nucleotide sequences of both RLN1 and RLN2 and acquired novel exons in the intergenic region between the genes. In order to investigate whether the RLN1-RLN2 fusion transcripts encode novel putative open reading frames (ORF) we analysed the sequences with the Translate Tool (Expasy, http://web.expasy.org/translate/). The shorter RLN1-RLN2-1 fusion transcript putatively translated into a RLN2 peptide with a truncated C-peptide and an A-chain, and was therefore not considered for further investigation. The analysis of the longer RLN1-RLN2-2 fusion transcript predicted a novel RLN2 isoform with an alternative start codon within a novel exon of the fusion (Fig. 3) . The new putative RLN2 isoform contained intact functional domains of RLN2 (B-chain, C-peptide and A-chain), but lost the entire signal sequence that is essential for its secretion via the endoplasmic reticulum (ER)-Golgi secretory pathway (Fig. 3) . Instead, the signal sequence was replaced by a short leader peptide MNTSKAVA (Fig. 3) . We also unveiled an LNCaP specific single nucleotide polymorphism in the C-peptide region of RLN2 (and of RLN1-RLN2-2) that affected the change of amino acid from isoleucine to asparagine in the sequence KKLI/NRNR ( Supplementary Fig. S2 ).
Identification of unique RLN1-RLN2 fusion and RLN1 regions
The RLN1-RLN2-2 fusion showed a significant overlap with the annotated RLN1 and RLN2 genes. In order to characterize the expression of the fusion, we aligned both novel fusion transcripts using the BLAT tool in the USCS genome browser (Kent, 2002; Kent et al., 2002) , and designed the qPCR primers in unique RLN1-RLN2-2 regions. The forward primer for specific detection of RLN1-RLN2-2 fusion was designed to span the junction between the novel exon of the fusion and the downstream fusion exon that is shared with the annotated RLN2. The reverse primer was designed in a region shared by RLN2 and RLN1-RLN2-2 fusion (Fig. 4A) . Similarly, we designed qPCR primers in the RLN1 unique region (Fig. 4A) . In order to test the specificity of the primers, we stably transfected LNCaP cells with a doxycycline inducible lentiviral vector encoding shRNA targeting the annotated RLN2 gene (shRLN2). LNCaP cells stably expressing non-targeting shRNA (shNT) were used as a control. The addition of doxycycline in shNT cells had no effect on the expression of RLN1-RLN2-2 fusion, whereas the addition of doxycycline to shRLN2 cells resulted in a significant decrease in the levels of RLN1-RLN2-2 fusion (Fig. 4B) . These results confirmed that the novel exon of the fusion is linked to the exon of the annotated RLN2 gene. RLN2 knock-down (shRLN2) had no effect on RLN1 levels. Although the expression of RLN1 decreased with doxycycline treatment, we observed no difference between the control (shNT) and shRLN2 cells, confirming the specificity of RLN1 primers (Fig. 4C) .
Underrepresentation of RLN1 in PCa cells
The RLN1-RLN2-2 fusion and RLN1 are overlapping same strand transcripts (Fig. 1) . We thus predicted an association between the expression of RLN1 and RLN1-RLN2-2 fusion. We first determined the expression of RLN1 in 3 normal and 7 PCa cell lines. RLN1 was abundantly expressed only in LNCaP cells, whereas in other PCa cells, the expression was >80-fold lower (Fig. 5A) . Similarly, the expression of the RLN1-RLN2-2 fusion was highest in LNCaP cells, and marginal in the other PCa cells (Fig. 5B) . The unexpected low expression of RLN1 in common PCa cell lines was a surprising observation as RLN1 is expressed in prostate tissue (Hansell et al., 1991) . We found further evidence of prostate tissue specific expression of RLN1 by accessing the Su et al. GeneAtlas microarray dataset (Fig. 5C) (Su et al., 2004) . Next, we examined a publically available TCGA RNA-Seq dataset from normal and PCa tissue samples to investigate whether the expression of RLN1 is limited to normal prostate tissue. We showed that both normal and PCa tissue expressed high levels of RLN1 (Fig. 5D) . The median expression of RLN1 in normal prostate tissue was 42.5 transcripts per million reads (TPM) and 12.7 TPM in PCa tissue.
RLN1-RLN2 fusion and RLN1 are inversely regulated by androgens
The expression of RLN2 has been shown to be negatively regulated by androgens in LNCaP cells (Thompson et al., 2006) . The androgen responsiveness of RLN2 led us to investigate the androgen regulation of the RLN1-RLN2-2 fusion and RLN1. Charcoal-stripped fetal bovine serum (CSS) was used to grow LNCaP cells in the absence of androgens for a period of 10 days. The removal of androgens resulted in a steady increase in the levels of the RLN1-RLN2-2 fusion (Fig. 6A) . Although the levels of RLN1 were higher in the absence of androgens, the increase was marginal in comparison to the RLN1-RLN2-2 fusion (Fig. 6A) . To further confirm that the increase in expression of the RLN1-RLN2-2 fusion was a result of androgens, we performed a similar experiment where LNCaP cells were first grown in CSS for 2 days followed by the 2 day treatment with androgens (10 nM DHT or 1 nM R1881). The treatment of LNCaP cells with androgens abolished the increase in expression of the RLN1-RLN2-2 fusion (Fig. 6B) . This androgen suppression resulted in 60e75% lower levels of RLN1-RLN2-2 fusion in androgen treated cells compared to control (Fig. 6B) . Contrary to the RLN1-RLN2-2 fusion, the addition of androgens resulted in upregulation of the expression of RLN1, indicating an inverse androgen regulation of the transcripts (Fig. 6C) . To further assure that the inverse androgen regulation of RLN1-RLN2-2 and RLN1 is a result of androgen directed signalling, we specifically inhibited the AR by doxycycline induced shRNA knock-down (shAR). DHT treatment in control cells (shNT) suppressed the expression of RLN1-RLN2-2 fusion in both doxycxyline induced and non-induced cells (Fig. 6D ). This suppression was still evident in non-induced shAR cells, but doxycycline induced AR knock-down impaired this suppression, confirming that androgen signalling down-regulates Fig. 3 . RLN1-RLN2-2 fusion encodes a putative RLN2 isoform without a signal peptide. Novel fusion RLN1-RLN2-2 is aligned with the currently annotated RLN2 peptide. The region with an alternative start codon is enlarged below. The entire signal sequence is deleted in the novel putative RLN2 isoform however the functional B-chain, C-peptide and A-chain are unchanged (downstream C-peptide and A-chain not shown). Fig. 4 . Identification of unique sequences of RLN1-RLN2-2 fusion and of RLN1. A. GENCODE V.19 RLN1 and RLN2 transcripts (black) are aligned to novel fusion transcripts RLN1-RLN2-1 and RLN1-RLN2-2. The canonical exons of RLN1 and RLN2 are overlaid to the fusion transcripts (gold rectangle) demonstrating the shared and unique regions of the transcripts. The arrows above transcripts represent the position of unique primer sets and the star represent the shRNA target sequence. The expression of B. RLN1-RLN2-2 and C. RLN1 after the doxycycline (DOX, 250 ng/ml) inducible knock-down of RLN2. (n ¼ 3; error bars, SE), *p < 0.05, ***p < 0.005. (For interpretation of the references to color in this figure caption, the reader is referred to the web version of this article.) the levels of RLN1-RLN2-2 (Fig. 6D) . Contrary to RLN1-RLN2-2, the expression of RLN1 was increased after DHT treatment in control cells, but this increase was suppressed by AR knock-down (Fig. 6E) . The changes in expression of the androgen responsive gene PSA were determined in all assays to confirm that the levels of androgens were depleted, or that the AR knock-down was efficient, and AR signalling decreased (Supplementary Fig. S4 ).
Discussion
In this study we used SMRT sequencing of full length RNA transcripts in PCa LNCaP cells in order to dissect the expression of RLN1, RLN2, and their transcript variants, and to identify unique sequences of RLN1 and RLN2 for more accurate characterization. We report on a novel abundantly expressed fusion transcript comprising the RLN1 and RLN2 genes which encodes a putative RLN2 isoform with an altered signal sequence domain that potentially modifies its mode of secretion. By employing a Sashimi Plot visualization of RNA-Seq data, we showed the presence of the unannotated fusion in both normal and PCa tissue. We designed unique RLN1-RLN2 fusion and RLN1 qPCR primers, and found that the RLN1-RLN2 fusion and RLN1 were co-expressed in various PCa cell lines but inversely regulated by androgens in LNCaP cells. We showed that RLN1 was surprisingly underrepresented in PCa cell lines in comparison to normal and PCa tissue.
We have identified a novel longer RLN2 transcript variant representing a fusion between RLN1 and RLN2 in LNCaP cells (Fig. 1) . Despite the use of northern blotting in previous PCa studies, longer RLN2 transcripts have not been observed (Ivell et al., 1989) . We have however used a recent state of the art SMRT sequencing technique and obtained RLN1-RLN2 fusion sequences in PCa cells (Fig. 1) . Additionally, we have observed fusion specific exons in RNA-Seq from normal and PCa tissues (Fig. 2B, C) . Further evidence of the RLN1-RLN2 fusion comes from a recent study where several longer RLN2 transcripts were predicted from de novo assembly of 7256 RNA sequencing (RNA-seq) libraries of tumors, normal tissue, and cell lines from 25 independent studies ( Supplementary Fig. S5 ) (Iyer et al., 2015) . The size of the fusion transcript was 2 kbp, making it twice the size of either RLN1 or RLN2. The expression and tissue specificity of RLN1, RLN2, and their variants, has been previously investigated using cloning techniques from cDNA libraries, northern blotting and qPCR (Garibay-Tupas et al., 2000; Gunnersen et al., 1996; Hudson et al., 1984) . Interestingly, initial northern blots performed in RNA samples from ovaries with RLN2 specific probes revealed a longer transcript of the similar size (2 kbp) as the fusion transcript we identified in PCa cells LNCaP . The longer variant was considered to be a potentially longer primary RLN2 mRNA species that was probably truncated into a mature RLN2 by cleavage in the alternative polyadenylation site but this had not been explored further. In another study, the longer 2 kbp variant of RLN2 was confirmed by northern blotting in ovaries, and interestingly the expression was found to be increasing with the luteal phase of the menstrual cycle (Ivell et al., 1989) . Thus, the evidence from the literature indicates that the longer RLN2 transcripts observed in the ovarian samples resemble the size of the novel RLN1-RLN2 fusion transcript identified in our study. Therefore, it would be interesting to investigate the expression of the RLN1-RLN2 fusion in ovaries.
The novel RLN1-RLN2 fusion putatively encodes a RLN2 isoform that retains all the functional domains of RLN2, but lacking the signal sequence responsible for secretion through the ER-Golgi complex and release into the cell exterior. The lack of a secretory signal could therefore obstruct the secretion of the RLN2 peptide from the cells. However, some secretory proteins lack the signal peptide and utilize alternative secretory pathways. For example, IL1b is a secretory inflammatory cytokine without a signal sequence and was consequently not found in the ER or Golgi but instead was translated by free polyribosomes (Lopez-Castejon and Brough, 2011) . One of the proposed secretory pathways of IL1b included shedding by microvesicles or exosomes. Interestingly, prostate gland epithelial cells are known to secrete vesicles called prostasomes into the seminal fluid (Sahlen et al., 2002 ). Thus, it is possible that the fusion encoded RLN2 isoform is secreted from prostate cells enclosed in prostasomes. The membrane enclosed RLN2 would have limited functionality in the seminal fluid and would be protected from degradation until reaching the target tissue. Opposing to the hypothesis of the prostasomal secretion of the fusion encoded RLN2, the RLN2 peptide identified in the seminal fluid was identical to the one isolated from the ovaries thus without a fusion specific alternative MNTSKAVA leader sequence (Winslow et al., 1992) . However in the mentioned study, RLN2 peptide was enriched from the sample of seminal fluid with an RLN2 antibody that might have failed to recognize the fusion encoded RLN2. In order to further investigate the cellular trafficking and function of the novel fusion encoded RLN2 isoform we aim to determine the precise nucleotide sequence of the fusion by sequencing of the cDNA clones and investigating its role in the next phase of our study.
The RLN1-RLN2 fusion has a significant overlap with RLN1 and RLN2 and thus unique regions are severely restricted (Figs. 1 and 3) , providing technical challenges for the accurate characterization of their expression. The fusion transcript overlapped the 3 0 end of the first and the 5 0 end of the second RLN1 exon, which represents a prime template for qPCR primers to be able to discriminate between mRNA and genomic DNA. However in the case of RLN1, primers designed near the exon junction would not be able to discriminate between RLN1 and RLN1-RLN2 fusion transcripts. Therefore we designed qPCR primers in unique RLN1 regions at the 3 0 end of the second exon. RLN1 specific primers were used previously, however their specificity was determined based on testing of different primer sets and selecting for those that were able to discriminate between the expression of RLN1 in corpus luteum and prostate tissue. For instance, RLN1 has been shown to be expressed in prostate tissue but not in the corpus luteum by northern blotting (Garibay-Tupas et al., 2000; Gunnersen et al., 1996) . Confirming the validity of our unique RLN1 region, the reverse primer for RLN1 in Fig. 6 . RLN1-RLN2-2 and RLN1 are inversely regulated by androgens. A. Relative gene expression of RLN1-RLN2-2 and RLN1 determined in a long-term androgen deprivation assay; RLN1-RLN2-2 (square), RLN1 (circle). B. Relative gene expression of RLN1-RLN2-2 and C. RLN1 determined in a short-term androgen deprivation assay; CSS (absence of androgens), DHT (physiological androgen, 10 nM), R1881 (synthetic androgen, 1nM), (n ¼ 3, error bars, SE). ****p < 0.001. D. Relative gene expression of RLN1-RLN2-2 and E. RLN1 in LNCaP cells stably expressing doxycycline (dox) inducible non-targeting shRNA [shNT] or shRNA targeting AR [shAR] determined in a short-term androgen deprivation assay; CSS (absence of androgens), DHT (physiological androgen, 10 nM), (n ¼ 3, error bars, SE). ****p<0.001; ns -non significant. both studies was designed in a region that we identified to be unique for RLN1 (Fig. 4) .
Using our specific RLN1 qPCR primers, we observed that RLN1 mRNA is underrepresented in PCa cell lines. We found that RLN1 was abundantly expressed only in LNCaP cells out of the 3 normal and 7 PCa cell lines tested. However, RLN1 has been shown to be expressed in the prostate tissue (Gunnersen et al., 1996; Hansell et al., 1991) . Specifically, we showed that RLN1 is a unique prostate tissue transcript (Fig. 5C ) and abundantly expressed in normal prostate and cancer tissue (Fig. 5D) . Thus, LNCaP cells best reflect the RLN1 expression observed in PCa and is the most relevant cell line for the use in further studies of RLN1 biology.
Androgens and androgen-regulated genes are important in the onset and progression of PCa. We observed that the RLN1-RLN2 fusion is down-regulated by androgens (Fig. 6B) . The suppression of annotated RLN2 was previously shown in LNCaP cells and tissues, however the primers used were unable to distinguish between RLN2 and the RLN1-RLN2 fusion (Thompson et al., 2006) . In the later study, the RLN1-RLN2 fusion transcript might have contributed to the majority of the qPCR signal considering the abundant expression of the fusion in LNCaP cells. Androgen regulation of RLN1 has not been previously shown, although Xu et al. showed AR binding upstream of the RLN1 gene, and co-regulation of RLN1 expression by AR and RNF6 (Xu et al., 2009) . We demonstrate that RLN1 was up-regulated by androgens (Fig. 6C, E) . Thus, we show here that although both RLN1 and the RLN1-RLN2 fusion transcript initiate from the same genomic locus and share parts of the genomic code, they are nevertheless inversely regulated by androgens. Since the transcription start site of RLN1 is located just upstream of the RLN1-RLN2 fusion, it would be interesting to investigate to what extent the transcription of RLN1 directly controls the expression of the fusion transcript.
In conclusion, our study implemented a state of the art SMRT sequencing technique in LNCaP cells, and identified a novel fusion transcript comprising the RLN1 and RLN2 genes. The fusion transcript encodes a putative RLN2 with a deleted secretory signal peptide indicating a potentially biologically important alteration. We have unveiled an association between the expression and regulation of RLN1-RLN2 fusion and RLN1, and discovered a surprising underrepresentation of RLN1 in PCa cell lines. Although RLN1-RLN2 was identified in PCa cells, we show evidence of its expression in normal prostate tissue. Further characterization of the RLN1-RLN2 fusion product will shed new light on its role in PCa as well as foster fundamental research in the field.
